4 analysts, average pt of $15, huge short interest, great entry
stop the madness. seriously. there are really two things that matter in this story. first, any change to the existing drugs on the market that lead to a better outcome while keeping the risks of use at least the same if not better for the user, will be viewed as a positive contribution. the FDA isn't evil, they understand the fat problem and therefore the voluntary diabetes problem that we have in this country. therefore, which brings me to my second point, BIOD, has a very good chance to get approval and we all know their PDUFA date on OCT 30th.
don't hate the winners, there are plenty of bio-techs to short, short the ones worth shorting.